President Donald Trump has reportedly signed off on a plan to remove FDA Commissioner Marty Makary, according to a Friday report citing sources familiar with internal deliberations, as tensions inside the administration continue to build.
The report indicates that senior officials have grown increasingly convinced Makary’s tenure may be nearing an end, pointing to months of internal turmoil and rising complaints from segments of the pharmaceutical industry. While the decision is not yet final and could still change, the development underscores deepening divisions within the administration over regulatory priorities and leadership at the Food and Drug Administration.
The reported move follows closely on the heels of another account earlier in the week that described Makary as being on “thin ice” after a clash with Trump over flavored vaping products. That dispute appears to have become a flashpoint, highlighting competing pressures between regulatory caution and political commitments made during the campaign.
According to those earlier details, Trump confronted Makary over what he viewed as a lack of urgency in advancing approvals for flavored vape and nicotine products. Advisers reportedly stressed the issue’s importance with younger MAGA voters, noting that Trump had repeatedly pledged during the 2024 campaign to “save” vaping.
Administration aides, according to the report, characterized Makary as an obstacle to that agenda, arguing he had slowed progress on policies seen as politically important. The tension reflects a broader struggle that often plays out in Washington: balancing public health concerns with campaign promises and shifting political priorities.
Makary had initially resisted approving certain flavored vape products—including menthol, mango, and blueberry varieties—from a Los Angeles-based manufacturer, citing concerns that such flavors could appeal to children. But under mounting pressure, he ultimately reversed course and approved the products earlier this week, shortly after details of his disagreement with the president became public.
Even so, the reversal appears to have done little to ease broader dissatisfaction. The report describes a wider pattern of friction during Makary’s tenure, with criticism coming from multiple directions, including anti-abortion activists, biotech firms, and advocates for patients with rare diseases.
Sources familiar with the situation said Makary has also clashed with colleagues within the health department on a range of policy issues, further complicating his position. In response, he has reportedly leaned on a small circle of advisers while seeking policy victories he could highlight to both the White House and the public.
The situation paints a picture of an agency caught between competing demands, where decisions on regulation can quickly become entangled in political considerations. While the focus in this case is on vaping policy, the broader tensions suggest a more systemic challenge in aligning regulatory agencies with evolving political goals.
For now, Makary remains in his post, and the president’s reported plan has not been finalized. But the uncertainty surrounding his future reflects an administration grappling with internal disagreements—where policy disputes, political messaging, and leadership questions are increasingly converging.
As the situation develops, it offers a reminder that even within a single administration, competing priorities can lead to sharp disagreements over direction, particularly when issues touch on both public health and political strategy.
[READ MORE: Trump Downplays Hantavirus Concerns as Cruise Ship Outbreak Raises Questions]
